Home » Authors » Kim Coghill

Articles by Kim Coghill

Velcade Performing Well In Confirmatory Phase III Trial

Dec. 16, 2003

Millennium Pharmaceuticals Inc. stopped dosing the control arm of a confirmatory Phase III trial of Velcade, a cancer drug, after an independent review committee uncovered positive data in a prespecified interim analysis. (BioWorld Today)

Velcade Performing Well In Confirmatory Phase III Trial

Dec. 16, 2003

Millennium Pharmaceuticals Inc. stopped dosing the control arm of a confirmatory Phase III trial of Velcade, a cancer drug, after an independent review committee uncovered positive data in a prespecified interim analysis. (BioWorld Today)

Acambis Files 'First-Ever' BLA: Arilvax Vaccine In Yellow Fever

Dec. 15, 2003

Acambis plc filed a biologics license application seeking approval of Arilvax as a vaccine to prevent yellow fever. (BioWorld Today)

Acambis Files 'First-Ever' BLA: Arilvax Vaccine In Yellow Fever

Dec. 15, 2003

Acambis plc filed a biologics license application seeking approval of Arilvax as a vaccine to prevent yellow fever. (BioWorld Today)

FDA Rule: Electronic Labeling For Drug Product Submissions

Dec. 12, 2003

FDA Rule: Electronic Labeling For Drug Product Submissions

Dec. 12, 2003

Guilford Raising $27.4M; Plans For Aggrastat, Aquavan In Line

Dec. 11, 2003

GlycoFi's Third Round Brings In $10M For Expansion Plans

Dec. 11, 2003

Guilford Raising $27.4M; Plans For Aggrastat, Aquavan In Line

Dec. 11, 2003

GlycoFi's Third Round Brings In $10M For Expansion Plans

Dec. 11, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...